<DOC>
	<DOCNO>NCT01830543</DOCNO>
	<brief_summary>The primary purpose study evaluate safety 2 different rivaroxaban treatment strategies one Vitamin K Antagonist ( VKA ) treatment strategy utilize various combination dual antiplatelet therapy ( DAPT ) low-dose aspirin ( ASA ) clopidogrel ( prasugrel ticagrelor ) .</brief_summary>
	<brief_title>A Study Exploring Two Strategies Rivaroxaban ( JNJ39039039 ; BAY-59-7939 ) One Oral Vitamin K Antagonist Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention</brief_title>
	<detailed_description>This open-label ( physician participant know treatment participant receives ) , randomize ( study medication assign chance ) , multicenter clinical study assess safety 2 rivaroxaban treatment strategy one vitamin K antagonist ( VKA ) treatment strategy participant , paroxysmal , persistent , permanent non-valvular atrial fibrillation ( AF ) percutaneous coronary intervention ( PCI ) stent placement . A target 2,100 participant randomize study , approximately 700 participant treatment strategy group . The randomization stratify intend duration DAPT ( 1 , 6 , 12 month ) . The study consist screen phase , 12-month open-label treatment phase , end-of-treatment/early withdrawal visit . The total duration participation study participant approximately 12 month .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Have document medical history paroxysmal , persistent , permanent nonvalvular atrial fibrillation ( AF ) Have undergo percutaneous coronary intervention ( PCI ) procedure ( stent placement ) primary atherosclerotic disease Must international normalize ratio ( INR ) 2.5 randomized Women must postmenopausal entry practice highly effective method birth control heterosexually active Be willing able adhere prohibition restriction specify study protocol Have condition contraindicates anticoagulant antiplatelet therapy would unacceptable risk bleeding , , limit : platelet count &lt; 90,000/microliter screening , history intracranial hemorrhage , 12 month history clinically significant gastrointestinal bleeding , nonVKA induce elevate prothrombin time ( PT ) screen Have anemia unknown cause hemoglobin level &lt; 10 g/dL ( &lt; 6.21 mmol/L ) Have history stroke Transient Ischemic Attack ( TIA ) Have calculate Creatinine Clearance ( CrCl ) &lt; 30 mL/min screening Have know significant liver disease liver function test ( LFT ) abnormality Have severe condition would limit life expectancy le 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Irregular heart beat</keyword>
	<keyword>rivaroxaban</keyword>
	<keyword>aspirin</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>prasugrel</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>vitamin K antagonist</keyword>
</DOC>